Leap Therapeutics reported that while the study showed some activity in biomarker populations, it failed to produce a decisive positive signal. The study's data suggested a high level of ...

Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...